Latest Articles about NVO

Novo Nordisk Rapidly Raising Dividend

Investor's Business Daily — Wed, 15 May 2013 01:49:00 Z

DrugmakerNovo Nordisk ( NVO ) has boosted its dividend sharply the past couple of years. The annual dividend was recently raised 29% to the equivalent of about $3.11 a share for holders of

Earnings and Sales Rise at Novo Nordisk - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 16:52:43 Z

Novo Nordisk ( NVO ) reported first quarter 2013 earnings of $1.94 per American Depository Receipt (ADR), up 32.5% from the year-ago period. Revenues in the first quarter of 2013

Novo Nordisk and EMIS Modify Deal - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 00:47:07 Z

Novo Nordisk A/S ( NVO ) and Emisphere Technologies, Inc. ( EMIS ) recently announced that they have modified their agreement for the development and commercialization of oral

Positive Data on Lilly Diabetes Candidate - Analyst Blog

Zacks Equity Research — Thu, 18 Apr 2013 23:17:53 Z

Eli Lilly and Company ( LLY ) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III

Pipeline Progresses at Shire - Analyst Blog

Zacks Equity Research — Sat, 06 Apr 2013 01:10:47 Z

Shire plc ( SHPG ) recently enrolled the first patients for two phase II studies of its candidate SRM003 (formerly Vascugel), which is being developed for treating patients suffering from

Glaxo Eyes Benlysta Label Expansion - Analyst Blog

Zacks Equity Research — Fri, 05 Apr 2013 23:09:05 Z

GlaxoSmithKline ( GSK ) recently announced that it has initiated a phase III study to evaluate the use of Benlysta (belimumab) in patients suffering from anti-neutrophil cytoplasmic

AstraZeneca Takes Over AlphaCore - Analyst Blog

Zacks Equity Research — Fri, 05 Apr 2013 01:09:40 Z

AstraZeneca 's ( AZN ) worldwide biologics research and development (R&D) unit, MedImmune recently acquired AlphaCore Pharma, a biotechnology company based in Michigan. Financial

Conditional EU Approval for Pfizer's Bosulif - Analyst Blog

Zacks Equity Research — Thu, 04 Apr 2013 23:08:00 Z

Pfizer Inc. ( PFE ) recently announced it has gained conditional marketing authorization from the European Commission (EC) for its oncology product, Bosulif (bosutinib). Bosulif gained

Court Rules Against AstraZeneca - Analyst Blog

Zacks Equity Research — Thu, 04 Apr 2013 01:22:08 Z

Recently, United States District Court for the District of New Jersey dealt a blow to AstraZeneca ( AZN ) when it ruled that a patent (6,598,603) protecting Pulmicort Respules (budesonide

Setback for Novartis in India - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 02:19:11 Z

Novartis ( NVS ) recently suffered a setback when the Indian Supreme Court denied patent for the company's oncology drug, Glivec (imatinib mesylate) under the Indian patent law. Novartis

Glaxo's Influenza Vaccine Gets CRL - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 02:50:01 Z

GlaxoSmithKline ( GSK ) recently received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the company's influenza vaccine candidate, Q-Pan H5N1

Pfizer's Xeljanz Approved in Japan - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 02:19:01 Z

Pfizer Inc. ( PFE ) recently announced that its rheumatoid arthritis treatment, Xeljanz, gained approval in Japan. The Japanese Ministry of Health, Labor and Welfare (MHLW) approved

Lilly Progresses with Empagliflozin - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 02:07:01 Z

Eli Lilly ( LLY ) and Boehringer Ingelheim recently submitted a New Drug Application (NDA) for their type II diabetes candidate, empagliflozin, in the US. Earlier this year, Eli Lilly

Sanofi Invests in Emerging Markets - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 01:10:27 Z

Sanofi ( SNY ) recently announced that it has started constructing a new manufacturing facility in the Saigon High Tech Park - Ho Chi Minh City, Vietnam. Sanofi plans to invest

Sanofi/Transgene Inks Immunotherapy Deal - Analyst Blog

Zacks Equity Research — Fri, 29 Mar 2013 02:30:43 Z

Sanofi ( SNY ) recently entered into a collaboration Transgene for the production of immunotherapy products and creating of an industrial platform for the same. The platform will include